Antigens, Neoplasm

• 

  Subject Areas on Research

  • A combination of two immunotoxins exerts synergistic cytotoxic activity against human breast-cancer cell lines. 
  • A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo. 
  • A multiphase immunotherapy regimen for human melanoma: clinical and laboratory results. 
  • A natural history of melanoma: serial gene expression analysis. 
  • A new Kupffer cell receptor mediating plasma clearance of carcinoembryonic antigen by the rat. 
  • A panel of antibodies useful in the cytologic diagnosis of metastatic melanoma. 
  • A preliminary study utilizing viable HLA mismatched cultured glioma cells as adjuvant therapy for patients with malignant gliomas. 
  • A serologic approach to the definition of human prostatic carcinoma antigens. 
  • A study of dendritic and endothelial cell interactions in colon cancer in a cell line and small mammal model. 
  • ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers. 
  • APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell-Mediated Antitumor Immune Responses. 
  • Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors. 
  • Abnormalitieis of monocyte chemotaxis in patients with melanoma: effects of immunotherapy and tumor removal. 
  • Abnormalities of circulating T-cell subpopulations in patients with cutaneous T-cell lymphoma: cutaneous lymphocyte-associated antigen expression on T cells correlates with extent of disease. 
  • Abundant tyrosine residues in the antigen binding site in anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Application to radiolabeling. 
  • Accurate identification of proliferative index in melanocytic neoplasms with Melan-A/Ki-67 double stain. 
  • Active specific immunotherapy of Dukes B2 and C colorectal carcinoma: comparison of two doses of the vaccine. 
  • Active-specific immunization against melanoma: is the problem at the receiving end? 
  • Acute lymphoblastic leukemia: classification and characterization with antisera to human T-cell and Ia antigens. 
  • Adoptive transfer and specific active immunization of patients with malignant melanoma. 
  • Alemtuzumab for the prevention and treatment of graft-versus-host disease. 
  • Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation. 
  • Alphavirus Replicon Particle Vaccine Breaks B Cell Tolerance and Rapidly Induces IgG to Murine Hematolymphoid Tumor Associated Antigens. 
  • Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals. 
  • An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. 
  • Analysis of factors associated with the tumorigenic potential of 12 tumor clones derived from a single rat colon adenocarcinoma. 
  • Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts. 
  • Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. 
  • Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models. 
  • Anti-tumor immunity: myeloid leukocytes control the immune landscape. 
  • Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. 
  • Antibody against T lymphoblastic leukemia-associated antigen (3-40) identifies vimentin and keratin intermediate filaments in normal cells. 
  • Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. 
  • Antigen-loaded monocyte administration induces potent therapeutic antitumor T cell responses. 
  • Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. 
  • Antigenic relationships between murine, feline and primate RNA tumor viruses and membrane antigens of human leukemic cells. 
  • Antigens of human pancreatic adenocarcinoma cells defined by murine monoclonal antibodies. 
  • Antigens shared by rat schwannomas, neuroblastomas, and a testicular interstitial cell carcinoma. 
  • Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection. 
  • Applications of monoclonal antibodies in the diagnosis and treatment of primary brain tumors. 
  • Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas. 
  • Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. 
  • Association Between Germline Mutation in VSIG10L and Familial Barrett Neoplasia. 
  • Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. 
  • Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. 
  • Augmentation of syngeneic tumor-specific immunity by semiallogeneic cell hybrids. 
  • Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial. 
  • Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment. 
  • B-lymphocytes from melanoma patients and normal individuals react with melanoma cells but also with irrelevant antigens. 
  • B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. 
  • Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. 
  • Biochemical, cell biological and immunological issues surrounding the endoplasmic reticulum chaperone GRP94/gp96. 
  • Biomarkers to help guide management of patients with pulmonary nodules. 
  • Bispecific antibodies engage T cells for antitumor immunotherapy. 
  • CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. 
  • CD40 ligand is essential for generation of specific cytotoxic T cell responses in RNA-pulsed dendritic cell immunotherapy. 
  • CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304. 
  • Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. 
  • Carbohydrate Microarrays Identify Blood Group Precursor Cryptic Epitopes as Potential Immunological Targets of Breast Cancer. 
  • Carbonic anhydrase IX in early-stage non-small cell lung cancer. 
  • Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification. 
  • Carcinoembryonic antigen binding proteins on elicited peritoneal macrophages. 
  • Carcinoma of the pancreas. Therapeutic efficacy as defined by a serodiagnostic test utilizing a monoclonal antibody. 
  • Cell adhesion protein expression in melanocytic matricoma. 
  • Cell surface reactive human monoclonal antibody directed to human melanoma-associated gangliosides. 
  • Cell-based vaccines for the stimulation of immunity to metastatic cancers. 
  • Cellular and biological therapies of gastrointestinal tumors: overview of clinical trials. 
  • Cellular immunity in rats with primary brain tumors: inhibition of macrophage migration by soluble extracts of avian sarcoma virus-induced tumors. 
  • Characterization of a chimpanzee anti-human melanoma antiserum. 
  • Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. 
  • Characterization of melanoma cell membrane tumor-associated antigens using xenoserum, alloserum, and autoserum: I. immunofluorescence. 
  • Characterization of renal neoplasms with monoclonal antibodies to leukocyte differentiation antigens. 
  • Classifying the evolutionary and ecological features of neoplasms. 
  • Clinical and biologic features predict a poor prognosis in acute lymphoid leukemias in infants: a Pediatric Oncology Group Study. 
  • Clinical applications of a peptide-based vaccine for glioblastoma. 
  • Clinical applications of dendritic cell vaccines. 
  • Comparative localization of glioma-reactive monoclonal antibodies in vivo in an athymic mouse human glioma xenograft model. 
  • Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. 
  • Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen. 
  • Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients. 
  • Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. 
  • Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. 
  • Costimulation blockade: towards clinical application. 
  • Cotransfection of DC with TLR4 and MART-1 RNA induces MART-1-specific responses. 
  • Cross-reacting antigens on L5178Y cells which serve as targets for cytotoxic T-lymphocyte lysis during establishment of the tumor dormant state. 
  • Cross-reactions of virally and chemically induced mouse sarcomas: surface expression of a common viral antigen. 
  • Current immunotherapeutic strategies in malignant melanoma. 
  • Cutting edge: CD91-independent cross-presentation of GRP94(gp96)-associated peptides. 
  • D6.1, a murine antimelanoma monoclonal antibody from congenitally athymic nude mice immunized with purified melanoma tumor-associated antigen. 
  • DU-PAN-2 levels in serum and pancreatic ductal fluids of patients with benign and malignant pancreatic disease. 
  • Deletion of CaMKK2 from the liver lowers blood glucose and improves whole-body glucose tolerance in the mouse. 
  • Delivery of Synthetic mRNA Encoding FOXP3 Antigen into Dendritic Cells for Inflammatory Breast Cancer Immunotherapy. 
  • Demonstration of complex antigenic heterogeneity in a human glioma cell line and eight derived clones by specific monoclonal antibodies. 
  • Dendritic cell-based immunotherapy. 
  • Dendritic cell-tumor cell fusion vaccines. 
  • Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. 
  • Depletion of human regulatory T cells. 
  • Detection and partial characterization of human thymus-leukemia antigens. 
  • Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma. 
  • Detection of both T-cell and Ia-like antigens on cells from patients with acute myelomonocytic leukemia and chronic myelogenous leukemia in blast crisis. 
  • Detection of early-stage pancreatic adenocarcinoma. 
  • Detection of minimal residual T cell acute lymphoblastic leukemia by flow cytometry. 
  • Detection of occult N2 disease with molecular techniques. 
  • Development and biological evaluation of ⁹⁹mTc-sulfonamide derivatives for in vivo visualization of CA IX as surrogate tumor hypoxia markers. 
  • Development of a radioimmunoassay for fetal antigen 2. 
  • Diagnostic value of three tumor markers determined in pleural effusions. 
  • Dietary isothiocyanate-induced apoptosis via thiol modification of DNA topoisomerase IIα. 
  • Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. 
  • Differentiation characteristics of newly established medulloblastoma cell lines (D384 Med, D425 Med, and D458 Med) and their transplantable xenografts. 
  • Differentiation of human T lymphocytes: II. Phenotypic difference in skin and blood malignant T-cells in cutaneous T-cell lymphoma. 
  • Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry. 
  • Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients. 
  • Direct vaccination with tumor cells killed with ICP4-deficient HSVd120 elicits effective antitumor immunity. 
  • Distribution and physical properties of BCA200, a Mr 200,000 glycoprotein selectively associated with human breast cancer. 
  • EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. 
  • ELAV tumor antigen, Hel-N1, increases translation of neurofilament M mRNA and induces formation of neurites in human teratocarcinoma cells. 
  • Editorial comment. 
  • Effect of radioiodination on the binding of monoclonal antibody DF3 to breast carcinoma cells. 
  • Elevation of multiple serum markers in patients with stage I ovarian cancer. 
  • Emerging immunotherapies for glioblastoma. 
  • Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. 
  • Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. 
  • Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma. 
  • Enzymatic susceptibility and spontaneous release of human melanoma tumor-associated antigens. 
  • EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model. 
  • EpCAM: A new therapeutic target for an old cancer antigen. 
  • Epigenetic Silencing of Recombinant Adeno-associated Virus Genomes by NP220 and the HUSH Complex. 
  • Epigenome-wide analysis of long-term air pollution exposure and DNA methylation in monocytes: results from the Multi-Ethnic Study of Atherosclerosis. 
  • Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs. 
  • Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases. 
  • Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. 
  • Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. 
  • Expression of a melanoma-tumor-associated antigen as demonstrated by a monoclonal antibody (D6.1) in cytopathologic preparations of human tumor cells from effusions and needle aspirates. 
  • Expression of human fetal brain antigens by human tumors of neuroectodermal origin as defined by monoclonal antibodies. 
  • Expression of major histocompatibility complex class I antigens in normal and transformed rat thyroid epithelial cell lines. 
  • Expression of protooncogene c-myb in normal human hematopoietic cells. 
  • Failure of monoclonal antibodies against tumor associated antigens to improve tumor targeting of LAK cells in a model of rat colon carcinoma. 
  • Fine-needle aspiration diagnosis of psammomatous melanotic schwannoma. 
  • Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines. 
  • Flow cytometric identification of intracellular antigens: detection of minimal residual leukemia. 
  • Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. 
  • Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes. 
  • Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. 
  • GRP94 (gp96) and GRP94 N-terminal geldanamycin binding domain elicit tissue nonrestricted tumor suppression. 
  • Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system. 
  • Generation of melanoma-specific, cytotoxic CD4(+) T helper 2 cells: requirement of both HLA-DR15 and Fas antigens on melanomas for their lysis by Th2 cells. 
  • Genetic architecture of gene expression traits across diverse populations. 
  • Genotypic divergence precedes clinical dissemination in a case of synchronous bilateral B-cell malignant lymphoma of the testes. 
  • Gigaxonin glycosylation regulates intermediate filament turnover and may impact giant axonal neuropathy etiology or treatment. 
  • Glioma-associated antigens defined by monoclonal antibodies against an avian sarcoma virus-induced rat astrocytoma. 
  • Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression. 
  • Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis. 
  • Glucose-regulated protein 94/glycoprotein 96 elicits bystander activation of CD4+ T cell Th1 cytokine production in vivo. 
  • Graft-versus-leukemia in the rat--the antileukemic efficacy of syngeneic and allogeneic graft-versus-host disease. 
  • HER2 dendritic cell vaccines. 
  • HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. 
  • HMGB1 released by irradiated tumor cells promotes living tumor cell proliferation via paracrine effect. 
  • Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity. 
  • Heat shock protein 96 is elevated in rheumatoid arthritis and activates macrophages primarily via TLR2 signaling. 
  • Hepatic angiomyolipoma and hepatic stellate cells share a similar gene expression profile. 
  • Hormone control and expression of androgen receptor coregulator MAGE-11 in human endometrium during the window of receptivity to embryo implantation. 
  • Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity. 
  • Human fetal brain antigen expression common to tumors of neuroectodermal tissue origin. 
  • Human galectin 3 binding protein interacts with recombinant adeno-associated virus type 6. 
  • Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. 
  • Human leukemia antigens: partial isolation and characterization. 
  • Human lymphocyte differentiation antigens HB-10 and HB-11. I. Ontogeny of antigen expression. 
  • Human melanoma and leukemia associated antigens difined by nonhuman primate antisera. 
  • I and i antigens on normal and leukemic leukocytes. 
  • IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphoma. 
  • ISO: a critical evaluation of the role of peptides in heat shock/chaperone protein-mediated tumor rejection. 
  • Id proteins synchronize stemness and anchorage to the niche of neural stem cells. 
  • Identification of a secreted Mr 95,000 glycoprotein in human melanocytes and melanomas by a melanocyte specific monoclonal antibody. 
  • Identification of a tumor associated antigen that can induce tumor specific cytotoxicity. 
  • Identification of aberrantly regulated genes in diseased skin using the cDNA differential display technique. 
  • Identification of an immunoreactive glycoprotein in the urine of sarcoma patients. 
  • Identification of human T cell leukemia virus in a Japanese patient with adult T cell leukemia and cutaneous lymphomatous vasculitis. 
  • Identification of novel epithelial ovarian cancer loci in women of African ancestry. 
  • Identification of resting cells by dual-parameter flow cytometry of statin expression and DNA content. 
  • Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. 
  • Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. 
  • Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. 
  • Identifying potential tumor markers and antigens by database mining and rapid expression screening. 
  • IgA transcytosis and antigen recognition govern ovarian cancer immunity. 
  • Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab. 
  • Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas. 
  • Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice. 
  • Immune response of chimpanzee to purified melanoma 250 kilodalton tumor-associated antigen. 
  • Immune selection after antigen-specific immunotherapy of melanoma. 
  • Immunobiology of human gliomas. 
  • Immunobiology of malignant astrocytomas. 
  • Immunodiagnosis of human malignancy. 
  • Immunogenicity of dendritic-tumor fusion hybrids and their utility in cancer immunotherapy. 
  • Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. 
  • Immunohistochemical expression of TAG-72 in normal and malignant endometrium: correlation of antigen expression with estrogen receptor and progesterone receptor levels. 
  • Immunolocalization of monoclonal antibody-defined extracellular matrix antigens in human brain tumors. 
  • Immunologic and clinicopathologic features of common acute lymphoblastic leukemia antigen-positive childhood T-cell leukemia. A Pediatric Oncology Group Study. 
  • Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. 
  • Immunophenotypic Shifts in Primary Cutaneous γδ T-Cell Lymphoma Suggest Antigenic Modulation: A Study of Sequential Biopsy Specimens. 
  • Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity. 
  • Immunoreactive prostatic specific antigen in male periurethral glands. 
  • Immunoregulatory T cells in cancer immunotherapy. 
  • Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow. 
  • Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. 
  • Immunotherapy for gynaecological malignancies. 
  • Immunotherapy for malignant melanoma with a tumor cell vaccine. 
  • Immunotherapy of cancer using dendritic cells. 
  • Immunotherapy of cancer with dendritic cell-based vaccines. 
  • Immunotherapy of cancer with dendritic-cell-based vaccines. 
  • Immunotherapy of malignant brain tumors. 
  • Immunotherapy of surgical malignancies. 
  • Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. 
  • In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. 
  • In vivo evaluation of cell mediated immunity against human melanoma. 
  • In vivo tumor localization using tumor-specific monkey xenoantibody, alloantibody, and murine monoclonal xenoantibody. 
  • Increased expression of sialyl-dimeric LeX antigen in liver metastases of human colorectal carcinoma. 
  • Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. 
  • Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy. 
  • Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. 
  • Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. 
  • Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. 
  • Induction of type I IFN is required for overcoming tumor-specific T-cell tolerance after stem cell transplantation. 
  • Inhibition of αvβ6 promotes acute renal allograft rejection in nonhuman primates. 
  • Interaction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas. 
  • Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells. 
  • Interrogation of individual intratumoral B lymphocytes from lung cancer patients for molecular target discovery. 
  • Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma; A clinical assessment. 
  • Investigative studies in the diagnosis and treatment of melanoma. 
  • Invited commentary. 
  • Involvement of histo-blood-group antigens in the susceptibility of colon carcinoma cells to natural killer-mediated cytotoxicity. 
  • Isolation and generation of human dendritic cells. 
  • Isolation of a human teratoma cell line which expresses F9 antigen. 
  • Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. 
  • L-selectin ligands expressed by human leukocytes are HECA-452 antibody-defined carbohydrate epitopes preferentially displayed by P-selectin glycoprotein ligand-1. 
  • Lacrimal Gland Tumors. 
  • Laser scanning cytometry evaluation of MART-1, gp100, and HLA-A2 expression in melanoma metastases. 
  • Leukotriene C4 induces migration of human monocyte-derived dendritic cells without loss of immunostimulatory function. 
  • Ligation of cell surface GRP78 with antibody directed against the COOH-terminal domain of GRP78 suppresses Ras/MAPK and PI 3-kinase/AKT signaling while promoting caspase activation in human prostate cancer cells. 
  • Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. 
  • Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. 
  • Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. 
  • MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation. 
  • MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response. 
  • MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer. 
  • MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele. 
  • Macrophages (histiocytes) in various reactive and inflammatory conditions express different antigenic phenotypes. 
  • Management of recurrent melanoma of the extremity. 
  • Melanoma brain metastasis: overview of current management and emerging targeted therapies. 
  • Melanoma patient antibody responses to melanoma tumor-associated antigens defined by murine monoclonal antibodies. 
  • Melanoma, a tumor based on a mutant stem cell? 
  • Mesothelin, a novel immunotherapy target for triple negative breast cancer. 
  • Metastatic choroidal melanoma to the contralateral orbit 40 years after enucleation. 
  • Monoclonal antibodies for brain tumour treatment. 
  • Monoclonal antibodies to antigens abnormally expressed in breast cancer. 
  • Monoclonal antibodies to different epitopes on a prostate tumor-associated antigen. Implications for immunotherapy. 
  • Monoclonal antibodies to human primary uveal melanomas demonstrate tumor heterogeneity. 
  • Monoclonal antibodies to tissue-associated antigens as antitumor reagents. 
  • Monoclonal antibodies to uveal melanoma. 
  • Monoclonal antibody against human T cell leukemia virus p19 defines a human thymic epithelial antigen acquired during ontogeny. 
  • Monoclonal antibody therapy of human gliomas: current status and future approaches. 
  • Monocytes as a Cellular Vaccine Platform to Induce Antitumor Immunity. 
  • Multiple assay characterization of murine monoclonal antimelanoma antibodies. 
  • Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity. 
  • Mutant p53 as an Antigen in Cancer Immunotherapy. 
  • Mutation near the polyoma DNA replication origin permits productive infection of F9 embryonal carcinoma cells. 
  • Non-specific and specific active immunotherapy in a B16 murine melanoma system. 
  • Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy. 
  • OVX1 as a marker for early stage endometrial carcinoma. 
  • OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures. 
  • Oncogenic Ras induces inflammatory cytokine production by upregulating the squamous cell carcinoma antigens SerpinB3/B4. 
  • Overexpression of human carcinoma-associated antigen in urothelial carcinoma of the bladder. 
  • Overview of melanoma vaccines and promising approaches. 
  • PSCA polymorphisms and gastric cancer susceptibility in an eastern Chinese population. 
  • Panel of serum biomarkers for the diagnosis of lung cancer. 
  • Partial purification and characterization of a murine glioma-associated antigen defined by syngeneic rat monoclonal antibodies. 
  • Pediatric oncology group utilization of immunologic markers in the designation of acute lymphocytic leukemia subgroups: influence on treatment response. 
  • Peptide/MHC tetramer-based sorting of CD8⁺ T cells to a leukemia antigen yields clonotypes drawn nonspecifically from an underlying restricted repertoire. 
  • Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1. 
  • Phenotypic characterization and ontogeny of mesodermal-derived and endocrine epithelial components of the human thymic microenvironment. 
  • Phenotypic characterization of cutaneous T-cell lymphoma. Use of monoclonal antibodies to compare with other malignant T cells. 
  • Polyoma virus infection of retinoic acid-induced differentiated teratocarcinoma cells. 
  • Posttranscriptional generation of macromolecular complexes. 
  • Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation. 
  • Potential leukemia virus subunit vaccines: discussion. 
  • Pre-T chronic lymphocytic leukemia with common acute lymphoblastic leukemia antigen. A new immunologic variant. 
  • Predicting and monitoring results of therapy. 
  • Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma. 
  • Primate-specific melanoma antigen-A11 regulates isoform-specific human progesterone receptor-B transactivation. 
  • Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines. 
  • Probing conformational changes in human DNA topoisomerase IIα by pulsed alkylation mass spectrometry. 
  • Proceedings: Immunologic similarities between fetal cell antigens and tumor cell antigens in guinea pigs. 
  • Production and characterization of two human glioma xenograft-localizing monoclonal antibodies. 
  • Production of monoclonal antibody alpha Pro3 recognizing a human prostatic carcinoma antigen. 
  • Prognostic marker analysis in pediatric intracranial ependymomas. 
  • Proliferating cell nuclear antigen expression to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors. 
  • Properties of prostatic cultures transformed by SV40. 
  • Prospects for the immunological management of lethal tumors. 
  • Prostate and transitional cell carcinoma: radioimmunoassay of viral tumor-associated antigens. 
  • Prostate cancer antigen 3 to select men for prostate biopsy: stop, go, or proceed with caution? 
  • Prostate cancer with solitary parotid metastasis correctly diagnosed with immunohistochemical stains. 
  • Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. 
  • Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. 
  • Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice. 
  • Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes. 
  • RNA transfected dendritic cells as cancer vaccines. 
  • RNA-Based Vaccines in Cancer Immunotherapy. 
  • RNA-transfected dendritic cells in cancer immunotherapy. 
  • RNA-transfected dendritic cells. 
  • Radioiodination of proteins using N-succinimidyl 4-hydroxy-3-iodobenzoate. 
  • Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody. 
  • Radioprotective effects of amifostine on acute and chronic esophageal injury in rodents. 
  • Re-evaluating the role of heat-shock protein-peptide interactions in tumour immunity. 
  • Recent developments in therapeutic cancer vaccines. 
  • Receptor-mediated endocytosis of carcinoembryonic antigen by rat alveolar macrophages in vitro. 
  • Regional localization of a glioma-associated antigen defined by monoclonal antibody 81C6 in vivo: kinetics and implications for diagnosis and therapy. 
  • Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. 
  • Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling. 
  • Relationships between membrane antigens of human leukemic cells and oncogenic RNA virus structural components. 
  • Relevance for neurobiology and neurooncology of antigens of malignant gliomas as defined by monoclonal antibodies. 
  • Rescuing imperfect antigens for immuno-oncology. 
  • Resistance of neoplasms to immunological destruction: role of a macrophage chemotaxis inhibitor. 
  • Rethinking Autoantibody Signature Panels for Cancer Diagnosis. 
  • Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion. 
  • Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer. 
  • Scavenger receptor-A mediates gp96/GRP94 and calreticulin internalization by antigen-presenting cells. 
  • Sensitive and specific detection of the 4B5 antigen in bronchial lavage specimens from patients with primary bronchogenic carcinoma. 
  • Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. 
  • Sequential adsorption analysis of antibodies to neuroectodermal cells by an indirect quantitative method. 
  • Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity. 
  • Serological response of non-human primates to human melanoma disialoganglioside GD3. 
  • Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response. 
  • Serum miR-638 Combined with Squamous Cell Carcinoma-Related Antigen as Potential Screening Biomarkers for Cervical Squamous Cell Carcinoma. 
  • Short-term kinetics of tumor antigen expression in response to vaccination. 
  • Significance of regional draining lymph nodes in the development of tumor immunity: implications for cancer immunotherapy. 
  • Similarities of fetal and tumor antigens of MCA-induced murine sarcomas. 
  • Solubilization and partial isolation of human melanoma tumor-associated antigens. 
  • Specific chromosomal abnormalities characterize four established cell lines derived from malignant human gliomas. 
  • Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens. 
  • Status of activation of circulating vaccine-elicited CD8+ T cells. 
  • Stem-like epithelial cells are concentrated in the distal end of the fallopian tube: a site for injury and serous cancer initiation. 
  • Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. 
  • Studies of tumor-infiltrating lymphocytes from a human choroidal melanoma. 
  • Superantigen enhanced protection against a weak tumor-specific melanoma antigen: implications for prophylactic vaccination against cancer. 
  • Suppression of human corneal epithelial proliferation with breast carcinoma immunotoxin. 
  • Surface antigenic characteristics of human glial brain tumor cells. 
  • Surface antigens of human glioma cells shared with normal adult and fetal brain. 
  • Surrogate markers of effective anti-tumor immunity. 
  • Synergy between tumor immunotherapy and antiangiogenic therapy. 
  • Synthesis and biological evaluation of a 99mTc-labelled sulfonamide conjugate for in vivo visualization of carbonic anhydrase IX expression in tumor hypoxia. 
  • T-Scan: A Genome-wide Method for the Systematic Discovery of T Cell Epitopes. 
  • T-cell-directed cancer vaccines: the melanoma model. 
  • Targeting Neoantigens in Hepatocellular Carcinoma for Immunotherapy: A Futile Strategy? 
  • Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies. 
  • Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. 
  • Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. 
  • Tetraspanin CD37 protects against the development of B cell lymphoma. 
  • The Cancer Epitope Database and Analysis Resource: A Blueprint for the Establishment of a New Bioinformatics Resource for Use by the Cancer Immunology Community. 
  • The DNA sequence of the human X chromosome. 
  • The Preuss Foundation Seminar on vaccine therapy for malignant primary brain tumors. February 15-17, 1998, La Jolla, Calif. 
  • The biology of malignant gliomas--a comprehensive survey. 
  • The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. 
  • The cutaneous lymphocyte antigen is an essential component of the L-selectin ligand induced on human vascular endothelial cells. 
  • The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). 
  • The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. 
  • The macrophage as an antineoplastic surveillance cell: biological perspectives. 
  • The messenger and the message: gp96 (GRP94)-peptide interactions in cellular immunity. 
  • The pathway to biomarker discovery: carbonic anhydrase IX and the prediction of immune responsiveness. 
  • The relationship of modulation of major histocompatibility complex class I antigens to retrovirus transformation in rat cell lines. 
  • The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. 
  • The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation. 
  • The tumor biology of melanoma nodal metastases. 
  • The tumor dormant state. 
  • The tumor dormant state. Comparison of L5178Y cells used to establish dormancy with those that emerge after its termination. 
  • The use of non-human primates for production of antisera to human tumor-associated antigens. 
  • The use of tumor markers in the management of patients with gynecologic carcinomas. 
  • Thermal dose fractionation affects tumour physiological response. 
  • Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes. 
  • Toxin-based targeted therapy for malignant brain tumors. 
  • Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. 
  • Transduction of human melanoma cells with the gamma interferon gene enhances cellular immunity. 
  • Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. 
  • Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression. 
  • Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection. 
  • Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. 
  • Treatment of refractory acute rejection in a lung transplant recipient with campath 1H. 
  • Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. 
  • Tumor antigens in astrocytic gliomas. 
  • Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. 
  • Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. 
  • Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine. 
  • Tumor membrane lymphocyte stimulation assay in patients with renal cell carcinoma. 
  • Tumor microenvironment and the immune response. 
  • Tumor resistance in rats immunized to fetal tissues. 
  • Tumor-associated antigen TAG-72: correlation of expression in primary and metastatic breast carcinoma lesions. 
  • Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients. 
  • Tumors as elusive targets of T-cell-based active immunotherapy. 
  • Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. 
  • Understanding the response to immunotherapy in humans. 
  • Unique proteins defined by monoclonal antibodies specific for human melanoma. Some potential clinical applications. 
  • Unusual chromosome architecture and behaviour at an HSR. 
  • Use of immunotoxins in combination to inhibit clonogenic growth of human breast carcinoma cells. 
  • Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer. 
  • Vaccination with T cell-defined antigens. 
  • Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen. 
  • Vaccine therapy in non-small-cell lung cancer. 
  • Variation by race in presenting clinical and biologic features of childhood acute lymphoblastic leukaemia: implications for treatment outcome. 
  • Virally induced lytic cell death elicits the release of immunogenic GRP94/gp96. 
  • Virus-cell relationships in dog brain tumors induced with Schmidt-Ruppin Rous sarcoma virus. 
  • Whole blood cells loaded with messenger RNA as an anti-tumor vaccine. 
  • [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis]. 
  • [Basis for a specific-active immunotherapy in malignant melanoma]. 
  • [Chicken RNA tumor viruses: a model for virus-induced carcinogenesis]. 
  • [Significance of monoclonal antibodies in diagnosis and therapy of tumors of the central nervous system]. 
  • p16 Improves interobserver agreement in diagnosis of anal intraepithelial neoplasia. 
  • p53 overexpression in advanced-stage endometrial adenocarcinoma. 
• 

  Keywords of People

  • Chitneni, Satish K., Associate Professor in Radiology, Radiology
  • Esclamado, Ramon Mitra, Richard Hall Chaney, Sr. Distinguished Professor Emeritus of Otolaryngology, Head and Neck Surgery & Communication Sciences
  • Lagoo, Anand Shreeram, Professor of Pathology, Pathology
  • Lee, Walter T, Professor of Head and Neck Surgery & Communication Sciences, Radiation Oncology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Patz Jr., Edward F., James and Alice Chen Distinguished Professor of Radiology, Pathology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Sullivan, Daniel Carl, Professor Emeritus of Radiology, Radiology
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Integrative Immunobiology